Ngalaba Mba Nile

Na Julaị 17, Center for Drug Evaluation (CDE) nke National Medical Products Administration (NMPA) kwupụtara na ngwa ahịa maka Trastuzumab Deruxtecan (Enhertu®) maka ọgwụgwọ nke abụọ nke kansa afọ abụrụla nke NMPA nabatara n'ihu ọha. Ngwa a dị n'ime...GỤKWUO»

N'oge na-adịbeghị anya, Ascentage Pharma kwupụtara na National Medical Products Administration (NMPA) nke mba China akwadola ọgwụ ọhụrụ ya nke na-egbochi Bcl-2 selective inhibitor lisaftoclax (APG-2575) maka ọgwụgwọ ndị okenye nwere ọrịa leukemia lymphocytic na-adịghị ala ala/small lymphocytic lymphoma (CLL/SLL).GỤKWUO»

N'oge na-adịbeghị anya, GenFleet Therapeutics kwupụtara na Ụlọ Ọrụ Nchịkwa Ọgwụ (ISAF) nke Mpaghara Nchịkwa Pụrụ Iche nke Macau nke China akwadola Dupert® (fulzerasib, GFH925/IBI351) maka ọgwụgwọ nke ndị ọrịa nwere kansa akpa ume na-abụghị obere mkpụrụ ndụ (NSCLC) nke nwere KRAS G12C mutati...GỤKWUO»

Na June 30, ọgwụ mgbochi MET nke Avistone mepụtara n'onwe ya, Vebreltinib, natara nkwenye ọnọdụ site na National Medical Products Administration (NMPA) nke China maka ọgwụgwọ ndị ọrịa nwere kansa akpa ume nke dị n'ógbè ahụ ma ọ bụ nke na-abụghị obere mkpụrụ ndụ kansa (NSCLC) nke nwere MET amplifi...GỤKWUO»

Na June 30, 2025, HUTCHMED kwupụtara na China National Medical Products Administration (NMPA) enyela ikike maka ojiji ọgwụ ọhụrụ (NDA) maka njikọta nke ORPATHYS (savolitinib) na TAGRISSO (osimertinib) maka ọgwụgwọ ndị ọrịa nwere ọrịa kansa ma ọ bụ kansa...GỤKWUO»

Na June 30, ebe nrụọrụ weebụ gọọmentị nke National Medical Products Administration (NMPA) kwupụtara na Anlotinib, ọgwụ ọhụrụ Klas 1 nke Chia Tai Tianqing mepụtara, enwetala nkwado maka ihe ngosi ọhụrụ na China: ọgwụgwọ njikọta na chemotherapy maka ọgwụgwọ mbụ nke ndị ọrịa ...GỤKWUO»

Na June 26, 2025, CARsgen kwupụtara na National Medical Products Administration (NMPA) nke China anabatala Ngwa Ọgwụ Ọhụrụ (NDA) maka satriccabtagene autoleucel ("satri-cel", CT041) (onye na-achọ ngwaahịa CAR T-cell onwe ya megide protein Claudin18.2) maka ọgwụgwọ Claudi...GỤKWUO»

Na June 19, Center for Drug Evaluation (CDE) nke National Medical Products Administration (NMPA) kwupụtara na a tụrụ aro ka a tinye ọgwụ LM-108 nke Livzon Pharmaceutical na nhazi ọgwụgwọ breakthrough. Njikọta nke ọgwụ mgbochi monoclonal nke Kefeqibai (LM-1...GỤKWUO»

Na June 19, Center for Drug Evaluation (CDE) nke National Medical Products Administration (NMPA) kwupụtara na a tụrụ aro IBI343 nke Innovent Biologics ka ọ tinye na mmemme nhazi ọgwụgwọ breakthrough, nke e mere maka ọgwụgwọ nke pan dị elu ma ọ bụ nke metastatic...GỤKWUO»

Na June 6, akwụkwọ akụkọ ahụike mba ụwa bụ Journal of Hematology & Oncology bipụtara nsonaazụ ọmụmụ nkebi nke I/II (KL264-01/MK-2870-001) nke TROP2 ADC sacituzumab tirumotecan (sac-TMT) ọhụrụ dị ka monotherapy maka etuto siri ike nke a na-apụghị ịgbanahụ n'ógbè ma ọ bụ nke na-anaghị agbanahụ nke na-anaghị emerụ ahụ...GỤKWUO»

Na June 10, Center for Drug Evaluation (CDE) nke National Medical Products Administration (NMPA) kwupụtara na a na-atụ aro ka a nye Trastuzumab Deruxtecan (T-DXd, DS-8201a) nyocha mbụ maka ọgwụgwọ ndị okenye nwere ọrịa afọ HER2 dị elu ma ọ bụ nke nwere ike ibute ọrịa...GỤKWUO»

N'oge na-adịbeghị anya, Merck & Co., Inc. (Merck) kwupụtara na National Medical Products Administration (NMPA) nke China akwadola ọgwụ mgbochi PD-1 ya, pembrolizumab, maka ojiji ya na lenvatinib na transarterial chemoembolization (TACE) maka ọgwụgwọ ndị ọrịa nwere ọrịa na-adịghị emerụ ahụ...GỤKWUO»